Drug profile · INN
epcoritamab
EPKINLY
epcoritamab (EPKINLY) is a b-lymphocyte antigen cd20 binding agent. Associated with AbbVie.
Drug details — epcoritamab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 13
- Data quality
- 0.83
Quick answer
epcoritamab (EPKINLY) is a b-lymphocyte antigen cd20 binding agent. Associated with AbbVie.
Key facts
Mechanism of action
B-lymphocyte antigen CD20 binding agent
Primary target: B-lymphocyte antigen CD20
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Bispecific Antibodies in Hematological Malignancies: Teclistamab, Mosunetuzumab & Epcoritamab FDA Review
This article delves into the FDA review of bispecific antibodies teclistamab, mosunetuzumab, and epcoritamab for hematological malignancies.
Bispecific Antibodies in Hematological Malignancies: Teclistamab & Market Trends 2025
Teclistamab is revolutionizing treatment for hematological malignancies, with emerging market trends set to influence bispecific antibody therapies by 2025.
Bispecific Antibody Therapies in B-Cell Lymphomas: FDA Approvals & Market Outlook
This article delves into FDA-approved bispecific antibody therapies for B-cell lymphomas, highlighting key drugs, their mechanisms, and future market trends.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is epcoritamab?
epcoritamab (EPKINLY) is a b-lymphocyte antigen cd20 binding agent. Associated with AbbVie.
What is the brand name for epcoritamab?
EPKINLY is a marketed brand name for epcoritamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.